

AUTHOR INDEX

- | | | |
|--|--|---|
| <p>Abdul-Karim, F.W., 96
 Abi-Rached, B., 42
 Allegra, C.J., 418
 Anasetti, C., 405
 Appelbaum, F.R., 405</p> <p>Belldegrün, A., 1, 74
 Berkowitz, R.S., 157, 166
 Biggs, D., 230
 Bilgrami, S., 307
 Brand, R., 448
 Buckner, C.D., 405
 Busch, E., 494
 Butturini, A., 374</p> <p>Chapman, A.E., 17
 Clift, R., 405
 Cohen, S.C., 218
 Coia, L.R., 611
 Cormis, R.L., 571
 Creaven, P.J., 509
 Crilley, P., 238</p> <p>DeBaz, B.P., 130
 Debruyne, F.M.J., 34
 Dewald, G.W., 341
 Dickstein, J.L., 355
 Doll, D.C., 305</p> <p>Feldman, S., 166
 Fenton, R.G., 9
 Figlin, R.A., 1, 74
 Freedman, G.M., 611
 Friedland, D.M., 571
 Fuchs, C.S., 472</p> <p>Gabrail, N.Y., 305
 Gale, R.P., 374
 Gewirtz, A.M., 210
 Ghosh, P., 9
 Giral, S., 396
 Gnarr, J.R., 3
 Goldfarb, J.M., 193
 Goldstein, D.P., 157, 166
 Goldstein, L.J., 17, 238
 Greenberg, B.R., 307
 Greenfield, A.W., 142</p> | <p>Gregorio, T.A., 9
 Grossman, S.A., 530</p> <p>Haller, D.G., 415
 Harris, D.T., 529, 553
 Herrington, S., 185
 Hoagland, H.C., 334
 Holderman, K., 448</p> <p>Jacobs, C., 540
 Jaffee, E.M., 81
 Johnston, P.G., 418</p> <p>Kantarjian, H., 396
 Kantoff, P.W., 625
 Kelsen, D.P., 582
 Kemeny, M.M., 494
 Kennedy, A.W., 161
 Klumpp, T.R., 263
 Komschlies, K.L., 9
 Kotz, K.W., 250
 Krigel, R.L., 218</p> <p>Lage, J.M., 113
 Lerman, M.I., 3
 Lewis, T.L., 130
 Linehan, M., 3
 List, A.F., 305
 Longo, D.L., 9
 Loret de Mola, J.R., 193</p> <p>Macfee, M.S., 95, 109
 Mangan, K.F., 202
 Mastrangelo, M.J., 647
 Matamoras, A., 448
 Mayer, R.J., 472
 Meropol, N.J., 509
 Moolten, D.N., 271
 Motzer, R.J., 641
 Murphy, W.J., 9</p> <p>Nathan, F.E., 647
 Nelson, R.L., 488
 Noel, P., 327
 Norris, L.K., 530
 Novick, A.C., 29</p> | <p>Oosterwijk, E., 34</p> <p>Pardoll, D.M., 81
 Parkinson, D.R., 61
 Peirce, W.C., 74
 Petrelli, N.J., 509
 Petrylak, D., 42
 Pinto, H., 540</p> <p>Radich, J., 405
 Rahgavan, D., 633
 Ratajczak, M.Z., 210
 Redline, R.W., 96
 Rose, P.G., 149</p> <p>Schalken, J.A., 34
 Schilder, R.J., 250
 Schilsky, R.L., 600
 Semer, D.A., 109
 Shulman, K., 600
 Silverstein, M.N., 327, 334
 Smith, M.R., 625
 Soper, J.T., 172
 Spiers, A.S.D., 380
 Stadler, W.M., 67
 Strom, B.L., 433
 Sznol, M., 61</p> <p>Talpaz, M., 396
 Tempero, M., 448
 Terreri, A., 327, 334
 Topolsky, D., 230
 Tyre, L., 121</p> <p>Vardiman, J.W., 355
 Vaughn, D.J., 415
 Vogelzang, N.J., 67</p> <p>Weinberg, D.S., 433
 Weiner, L.M., 201
 Wiltroft, R.H., 9
 Wolf, N.G., 113
 Wright, P., 341</p> <p>Yagoda, A., 42</p> <p>Zbar, B., 3</p> |
|--|--|---|

SUBJECT INDEX

- | | |
|---|---|
| <p>Ab2 vaccine, in renal cell cancer, 37-40
 Ab3 sera, 39
 ABL, in chronic granulocytic leukemia, 344
 Abortion, spontaneous, in polycythemia rubra vera, 312
 Acivicin, in renal cell cancer, 44
 Aclarubicin, in renal cell cancer, 44
 Actinomycin
 dosing of, in complete molar pregnancy, 159
 in gestational trophoblastic disease, 147</p> | <p>Adenosine deaminase deficiency, 281
 Adherent lymphokine activated killer cell, 375
 Adjuvant chemotherapy
 of brain tumor, 530-539
 in breast cancer, 553-570
 with cisplatin, vinblastine, bleomycin regimen, for testis cancer, 642-643
 in CNS lymphoma, 536
 of colon cancer, 600-610</p> |
|---|---|

AUTHOR INDEX

- | | | |
|---|--|---|
| <p>Abdul-Karim, F.W., 96
 Abi-Rached, B., 42
 Allegra, C.J., 418
 Anasetti, C., 405
 Appelbaum, F.R., 405</p> <p>Belldregun, A., 1, 74
 Berkowitz, R.S., 157, 166
 Biggs, D., 230
 Bilgrami, S., 307
 Brand, R., 448
 Buckner, C.D., 405
 Busch, E., 494
 Butturini, A., 374</p> <p>Chapman, A.E., 17
 Clift, R., 405
 Cohen, S.C., 218
 Coia, L.R., 611
 Cormis, R.L., 571
 Creaven, P.J., 509
 Crilly, P., 238</p> <p>DeBaz, B.P., 130
 Debruyne, F.M.J., 34
 Dewald, G.W., 341
 Dickstein, J.L., 355
 Doll, D.C., 305</p> <p>Feldman, S., 166
 Fenton, R.G., 9
 Figlin, R.A., 1, 74
 Freedman, G.M., 611
 Friedland, D.M., 571
 Fuchs, C.S., 472</p> <p>Gabrail, N.Y., 305
 Gale, R.P., 374
 Gewirtz, A.M., 210
 Ghosh, P., 9
 Giral, S., 396
 Gnarr, J.R., 3
 Goldfarb, J.M., 193
 Goldstein, D.P., 157, 166
 Goldstein, L.J., 17, 238
 Greenberg, B.R., 307
 Greenfield, A.W., 142</p> | <p>Gregorio, T.A., 9
 Grossman, S.A., 530</p> <p>Haller, D.G., 415
 Harris, D.T., 529, 553
 Herrington, S., 185
 Hoagland, H.C., 334
 Holderman, K., 448</p> <p>Jacobs, C., 540
 Jaffee, E.M., 81
 Johnston, P.G., 418</p> <p>Kantarjian, H., 396
 Kantoff, P.W., 625
 Kelsen, D.P., 582
 Kemeny, M.M., 494
 Kennedy, A.W., 161
 Klumpp, T.R., 263
 Komschlies, K.L., 9
 Kotz, K.W., 250
 Krigel, R.L., 218</p> <p>Lage, J.M., 113
 Lerman, M.I., 3
 Lewis, T.L., 130
 Linehan, M., 3
 List, A.F., 305
 Longo, D.L., 9
 Loret de Mola, J.R., 193</p> <p>Macfee, M.S., 95, 109
 Mangan, K.F., 202
 Mastrangelo, M.J., 647
 Matamoras, A., 448
 Mayer, R.J., 472
 Meropol, N.J., 509
 Moolten, D.N., 271
 Motzer, R.J., 641
 Murphy, W.J., 9</p> <p>Nathan, F.E., 647
 Nelson, R.L., 488
 Noel, P., 327
 Norris, L.K., 530
 Novick, A.C., 29</p> | <p>Oosterwijk, E., 34</p> <p>Pardoll, D.M., 81
 Parkinson, D.R., 61
 Peirce, W.C., 74
 Petrelli, N.J., 509
 Petrylak, D., 42
 Pinto, H., 540</p> <p>Radich, J., 405
 Rahgavan, D., 633
 Ratajczak, M.Z., 210
 Redline, R.W., 96
 Rose, P.G., 149</p> <p>Schalken, J.A., 34
 Schilder, R.J., 250
 Schilsky, R.L., 600
 Semer, D.A., 109
 Shulman, K., 600
 Silverstein, M.N., 327, 334
 Smith, M.R., 625
 Soper, J.T., 172
 Spiers, A.S.D., 380
 Stadler, W.M., 67
 Strom, B.L., 433
 Sznol, M., 61</p> <p>Talpaz, M., 396
 Tempero, M., 448
 Terreri, A., 327, 334
 Topolsky, D., 230
 Tyre, L., 121</p> <p>Vardiman, J.W., 355
 Vaughn, D.J., 415
 Vogelzang, N.J., 67</p> <p>Weinberg, D.S., 433
 Weiner, L.M., 201
 Wiltro, R.H., 9
 Wolf, N.G., 113
 Wright, P., 341</p> <p>Yagoda, A., 42</p> <p>Zbar, B., 3</p> |
|---|--|---|

SUBJECT INDEX

- | | |
|---|---|
| <p>Ab2 vaccine, in renal cell cancer, 37-40
 Ab3 sera, 39
 ABL, in chronic granulocytic leukemia, 344
 Abortion, spontaneous, in polycythemia rubra vera, 312
 Acivicin, in renal cell cancer, 44
 Aclarubicin, in renal cell cancer, 44
 Actinomycin
 dosing of, in complete molar pregnancy, 159
 in gestational trophoblastic disease, 147</p> | <p>Adenosine deaminase deficiency, 281
 Adherent lymphokine activated killer cell, 375
 Adjuvant chemotherapy
 of brain tumor, 530-539
 in breast cancer, 553-570
 with cisplatin, vinblastine, bleomycin regimen, for testis cancer, 642-643
 in CNS lymphoma, 536
 of colon cancer, 600-610</p> |
|---|---|

- Adjuvant chemotherapy (*Continued*)
 in colorectal cancer, 472-487
 definition of, 472, 532
 in ependymoma, 536
 of gastric cancer, 590-592
 goal of, 532
 in head and neck cancer, 540-552
 in high-grade astrocytoma, 533-534
 for invasive bladder cancer, 625-632
 in medulloblastoma, 536
 for melanoma, 647-661
 multi-institutional trials of, in colon cancer, 604
 need for, in rectal cancer, 611
 neoadjuvant v. for invasive bladder cancer, 629-630
 in node-negative patients, 554-555, 564-566
 in node-positive patients, 553-554, 564
 nonsystemic, for melanoma, 656-657
 in NSCLC, 571-581
 overview of, 529
 of pancreatic cancer, 595-596
 patient selection for, 585-586
 portal vein, 476-477, 604-605
 postoperative, timing of, in esophageal cancer, 587
 practical considerations in, 564-566
 preoperative, in rectal cancer, 611-612
 preoperative v postoperative, in rectal cancer, 616-617
 in prostate cancer, 633-640
 randomized trials of, in NSCLC, 573
 rationale for, 474
 single agent, in colorectal cancer, 474-475
 in stage II nonseminomatous testis cancer, 641-646
 surveillance v. in testis cancer, 643
 trials of, in rectal cancer, 481-482
 in upper gastrointestinal tract cancers, 582-599
 with folinic acid plus 5-FU, trials of, 602-604
- AG337, 515
- Age
 in choriocarcinoma, 111
 in colon cancer, 440
 in gestational trophoblastic disease, 110
 in matched sibling transplantation, for chronic myelogenous leukemia, 406
 polycythemia rubra vera treatment by, 319
- Agnogenic myeloid metaplasia
 bone marrow fibrosis in, 327-328
 clinical features of, 329
 cytogenetics of, 348-349
 diagnosis of, 328-329
 experimental therapy in, 331
 medical management of, 330
 prognosis in, 329-330
 radiation treatment in, 331
 splenectomy in, 330-331
- Alanosine, in renal cell cancer, 44
- Alkylating agents, in renal cell cancer, 52
- Allele, chromosome
 clinical significance of, 421-422
 in colorectal cancer, 419, 421
- Ametrantrone, in renal cell cancer, 44
- Aminothiazole, in renal cell cancer, 44
- Amiodarone, as chemosensitizing agent, 23
- Amonafide, in renal cell cancer, 44
- Amphotericin B
 as chemosensitizing agent, 23
 lomustine plus, in renal cell cancer, 48
- Ampligen, in renal cell cancer, 44
- Amsacrine, in renal cell cancer, 44
- A-myb protein, 215
- Anagrelide, 319
 in agnogenic myeloid metaplasia, 331
 in essential thrombocythemia, 337
- Anemia
 in agnogenic myeloid metaplasia, 329
 autoimmune hemolytic, in chronic granulocytic leukemia, 393
 in chronic granulocytic leukemia metamorphosis, 392
 due to stem cell harvesting, 264
 hypoproliferative, 267
- Anoikis, 213
- Anthracyclines
 in adjuvant chemotherapy, for breast cancer, 554
 in renal cell cancer, 53
- Anti-antibodies, 37-38
- Anti-idiotypic antibody, monoclonal antibody G250-related, 37-40
- Antibody 3H1, in colorectal cancer, 425-426
- Antibody purging, in stem cell collections, 274-275
- Antibody therapy, in colorectal cancer, 425
- Antifols, in renal cell cancer, 52
- Antigen preserving cell, professional, 13
- Antigen-supplemented whole tumor cells, for melanoma, 655
- Antimitotics, in renal cell cancer, 51-52
- Antisense oligonucleotide, 275
- apc gene, 419
 and c-myc activity, 424
- Aspirin, in polycythemia rubra vera, 316
- Astrocytoma, high-grade
 adjuvant chemotherapy of, 533
 adjuvant chemotherapy results in, 533-534
 carmustine adjuvant therapy in, 533-534
 carmustine neoadjuvant therapy in, 535-536
 cisplatin neoadjuvant therapy in, 535-536
 dissemination of, 531-532
 intra-arterial chemotherapy in, 534
 neoadjuvant therapy of, 535
 neoadjuvant therapy results in, 535-536
 procarbazine, lomustine, vincristine regimen in, 533
 survival in, 533
- ATP binding cassette, 17
- Atypical myeloproliferative syndrome, cardinal features of, 381
- Autolymphocyte cellular therapy, in renal cell cancer, 74-75
- 5-Aza-2'-Deoxycytidine, in renal cell cancer, 44
- Bacille Calmette-Guerin
 in adjuvant therapy, 647-649
 in colon cancer, 605-606
 for melanoma, 650-652
 trials of, in NSCLC, 573-576
- Bacteremia, due to stem cell harvesting, 264
- Barium enema, in colon cancer screening, 439

- Basic fibroblast growth factor, 214
- Bcl-2 gene, 275
- BCNU, *see* Carmustine
- BCR, in chronic granulocytic leukemia, 344
- BCR-ABL fusion
- in chronic granulocytic leukemia, 344-345
 - in chronic myelogenous leukemia, 374-375
- Bepiridil, as chemosensitizing agent, 23
- Biochemical modulation, of 5-FU, in metastatic colorectal cancer, 509-524
- Biologic response modifier, in colon cancer, 606
- Biomarker(s)
- candidate, in colon cancer, 443
 - in colon cancer screening, 442
- Bisantrene, in renal cell cancer, 44
- Bladder cancer, invasive
- adjuvant therapy for, 625-632
 - neoadjuvant therapy for, 625-632
 - treatment recommendations for, 630-631
- Blastic crisis, in chronic granulocytic leukemia metamorphosis, 391
- Bleeding, in polycythemia rubra vera, 311
- Bleomycin
- in neoadjuvant therapy, for head and neck cancer, 541
 - in neoadjuvant trials, for head and neck cancer, 542-543
- Bleomycin, cisplatin, vinblastine regimen, as adjuvant therapy, 642-643
- Blighted ovum, 98
- Blindness, monocular, in polycythemia rubra vera, 312
- Blood center, in PBSC transplantation, 283-284
- Blood transfusion, in hepatic resection, 496
- BMT, *see* Bone marrow transplantation
- B-myb protein, 215
- Bone marrow, in polycythemia rubra vera, 313
- Bone marrow fibrosis
- causes of, 328
 - diagnosis of, 328-329
 - pathogenesis of, 327-328
- Bone marrow transplantation
- allogeneic
 - in chronic myelogenous leukemia, 397-398
 - in multiple myeloma, 231-232
 - autologous
 - in chronic myelogenous leukemia, 408
 - in high-dose chemotherapy trials, 563
 - in metastatic breast cancer, 240-242
 - in multiple myeloma, 232
 - peripheral progenitor cell transplant, 242-243
 - CA-125 in, 258-259
 - cures due to, in chronic myelogenous leukemia, 409-410
 - HLA-identical sibling, in chronic myelogenous leukemia, 405-407
 - matched sibling, in advanced chronic myelogenous leukemia, 407
 - mismatched family member, in chronic myelogenous leukemia, 407
 - unrelated donor, in chronic myelogenous leukemia, 407-408
- Brain tumor, primary (*Continued*)
- neoadjuvant chemotherapy of, 530-539
 - radiotherapy of, 185-188, 530
- Breast cancer
- adjuvant chemohormonal therapy in, 556-558
 - adjuvant hormonal therapy in, 555-556
 - adjuvant systemic therapy in, 553-570
 - autologous BMT v, peripheral progenitor cell transplant in, 242-243
 - bone marrow support in, 240-242
 - chemotherapy dose intensity in, 238-240, 561-563
 - chemotherapy dose intensity trials in, 559
 - chemotherapy dose sequencing in, 563-564
 - cyclophosphamide, methotrexate, 5-FU regimen in, 553
 - high-dose chemotherapy trials in, 563
 - high-dose therapy in, 240-242
 - metastatic, 240-242
 - national randomized trials in, of high-dose therapy, 242
 - node-negative, adjuvant chemotherapy in, 554-555, 564-566
 - node-positive, adjuvant chemotherapy in, 553-554, 564
 - ovarian ablation in, 558-559
 - overview analysis in, 560-561
 - peripheral blood stem cell transplantation in, 238-249
 - stage II, 242
 - stage III, 242
- Budd-Chiari syndrome, in polycythemia rubra vera, 312
- Burst-forming units-erythroid, 308
- Busulfan
- in chronic granulocytic leukemia, 387-388
 - in chronic myelogenous leukemia, 396-397
 - in matched sibling BMT, 406
 - in peripheral blood progenitor cell transplantation, 233
 - in polycythemia rubra vera, 317
- Busulfan lung, 387
- Bystander effect, 282-283
- CA 19-9 antigen, radioimmunodetection of, 448
- CA-125, in BMT, 258-259
- Camptothecin, 515-516
- Carbohydrates, in human chorionic gonadotropin, 123
- Carboplatin
- cisplatin v, in ovarian cancer, 251
 - high-dose, 251
 - in high-dose combination regimen, for ovarian cancer, 256-257
 - in neoadjuvant therapy, for head and neck cancer, 541
 - in renal cell cancer, 44
- Carcinoembryonic antigen
- in colorectal cancer, 425-426
 - in liver metastasis detection, 495
 - radioimmunodetection of, 448
- Cardiac valve, abnormalities of, in polycythemia rubra vera, 312
- Carmustine
- as adjuvant therapy, in high-grade astrocytoma, 533-534
 - etoposide, cytarabine, cyclophosphamide regimen, high-dose, 220
 - etoposide, cytarabine, melphalan regimen, high-dose, 220
 - in neoadjuvant therapy, for high-grade astrocytomas, 535-536
 - in peripheral blood progenitor cell transplantation, 233
- Catheter, central venous, occlusion of, 263-264
- CB3717, 515

- CCNU, *see* Lomustine
- CD34 antigen
 direct positive selection of, 204-205
 identification of, 203
- CEA, *see* Carcinoembryonic antigen
- Cell proliferation, detection of, in colon cancer, 442
- Cell staining, in stem cell tumor detection, 273
- Cellular therapy
 autolymphocytes for, 74-75
 in renal cell cancer, 74-80
 LAK cells for, 75-76
 tumor-infiltrating lymphocytes for, 76-78
- Central nervous system
 gestational trophoblastic disease metastatic to, 137-139
 high-risk gestational trophoblastic disease metastatic to, 179
- Central venous catheter, occlusion of, 263-264
- Centrifugation, for stem cell isolation, 212
- Chemoembolization, for hepatic metastases, 503
- Chemohormonal therapy, adjuvant, in breast cancer, 556-558
- Chemoimmunotherapy, in colon cancer, 606
- Chemokines, transfectants for, 13-14
- Chemoprophylaxis
 data supporting, 157-158
 of hydatidiform mole, 157-160
 opposition to, 158
- Chemoradiotherapy
 concurrent, 545-547
 in esophageal cancer, 589-590
 in gastric cancer, 593
 in head and neck cancer, 545-548
 in NSCLC, 578-579
 postoperative, in rectal cancer, 613-616
 preoperative, trials of, 613
 without surgery, in esophageal cancer, 589
 in upper gastrointestinal tract cancers, 584-585
- Chemosensitizing agents, 23
- Chemotherapy
 adjuvant, *see* Adjuvant chemotherapy
 in breast cancer, 238-240
 combination, *see* Combination chemotherapy
 dose intensity of, in breast cancer, 561-563
 dose sequencing of, in breast cancer, 563-564
 in gestational trophoblastic disease, 147
 hepatic arterial, in colorectal cancer, 501-503
 high-dose, *see* High-dose chemotherapy
 in high-grade astrocytoma, 533
 in high-risk gestational trophoblastic disease, 177-179
 hormonal therapy plus, *see* Chemohormonal therapy
 by intrahepatic pump, 502-503
 infertility following, 196
 interstitial, in high-grade astrocytoma, 534
 intra-arterial, in high-grade astrocytoma, 534
 intraperitoneal, in gastric cancer, 594-595
 in ovarian cancer, 250-251
 in PBSC mobilization, 204-205
 perioperative, definition of, 571
 in persistent gestational trophoblastic disease, 162-163
 pregnancy outcome following, 196
 in primary brain tumor, 530-531
 radiotherapy alternating with, in head and neck cancer, 547
 radiotherapy following
- Chemotherapy (*Continued*)
 in esophageal cancer, 590
 in head and neck cancer, 547
 radiotherapy plus, *see* Chemoradiotherapy
 regional, in colorectal cancer, 501-503
 toxicities associated with, rescue from, 517-519
 see also Combined modality therapy
- Chlorambucil
 acute leukemia following, 314
 in gestational trophoblastic disease, 177
 in polycythemia rubra vera, 315
- CHOP regimen, *see* Cyclophosphamide, doxorubicin, vincristine, prednisone regimen
- Chorioadenoma destruens, sonography in, 131
- Choriocarcinoma, 101, 116-117
 atypical, 102
 epidemiology of, 110-111
 incidence of, 111
 metastatic, 138
 MRI of, 136
 pathology of, 103-104
 prognostic factors in, 104
 risk factors for, 111
 sonography of, 131-132
- Chromosome 17p, in colorectal cancer, 420-421
- Chromosome 18q, in colorectal cancer, 420-421
- Chromosome abnormality(ies)
 clonality of, 343
 in myeloproliferative disorders, 341-354
 secondary, 343
- Chromosome allele
 clinical significance of, 421-422
 in colorectal cancer, 419, 421
- Chromosome evolution, 343
- Chronic granulocytic leukemia
 accelerated phase in, 359
 atypical presentation of, 385-387
 blast phase in, 358
 busulfan in, 387-388
 cardinal features of, 381
 chronic phase in, 355
 clinical features of, in metamorphosis, 388-392
 clinical manifestations of, 380-395
 clinical picture of, following initial therapy, 387-388
 clinical presentations of, 381-385
 cytogenetics of, 344-346
 definition of, 380
 diagnosis of, 360, 381, 384, 387
 differential diagnosis of, 358-362
 early, 381-382
 epidemiology of, 380-381
 hematopathologic findings in, 355
 history in, 381, 382, 385

- Chronic granulocytic leukemia (*Continued*)
- hydroxyurea in, 387-388
 - interferon alpha in, 387-388
 - laboratory features in, 393-394
 - major features of, 368
 - management of, 382, 384-385, 387
 - in metamorphosis, hematological changes during, 391
 - metamorphosis progression in, 392-393
 - peripheral blood findings in, 381, 383-384, 386-387
 - Ph-negative, 346
 - physical examination in, 381, 382-383, 385-386
 - radiologic findings in, 381, 383, 386
 - typical presentation of, 382-385
- Chronic idiopathic myelofibrosis
- characteristics of, 367-368
 - evolution of, 368
 - major features of, 368
 - marrow fibrosis diagnosis and, 368-369
- Chronic myelogenous leukemia
- accelerated-phase, therapy in, 400
 - advanced-phase, matched sibling transplantation in, 407
 - as cancer development model, 374-379
 - atypical, 360-362
 - autologous BMT in, 408
 - blastic-phase of, therapy in, 400-401
 - BMT cures in, 409-410
 - BMT for, 405-411
 - chronic-phase, matched sibling transplantation in, 405-407
 - diagnosis of, 360
 - early chronic phase of, therapy for, 397-398
 - hematopoiesis, in chronic phase, 375
 - HHT in, 401
 - HLA-identical sibling transplantation in, 405
 - investigational therapies for, 401
 - minimal residual disease in, following BMT, 408-409
 - mismatched family member BMT in, 407
 - peripheral blood stem cell transplantation in, 401
 - post-transplant relapse in, 409
 - syngeneic transplantation in, 405
 - therapeutic goals in, 396-397
 - transformation in, 374-375
 - treatment of, 396-404
 - unrelated donor BMT in, 407-408
- Chronic myelomonocytic leukemia, 360-362
- cardinal features of, 381
 - diagnosis of, 360
- Chronic neutrophilic leukemia, 360
- cardinal features of, 381
 - characteristics of, 361
- Cimetidine
- coumarin plus, 44
 - interferon plus, 44
- Ciprofloxacin, 562
- Cisplatin
- carboplatin v, in ovarian cancer, 251
 - in chemoradiotherapy
 - for head and neck cancer, 546-547
 - for NSCLC, 578
 - high-dose, 251
 - in high-dose combination regimen, for ovarian cancer, 256-257
- Cisplatin (*Continued*)
- high-dose trials of, in breast cancer, 563
 - for invasive bladder cancer, 625, 627
 - in neoadjuvant therapy
 - for head and neck cancer, 541
 - for high-grade astrocytomas, 535-536
 - in neoadjuvant trials, for head and neck cancer, 542-543
 - randomized trials of, in NSCLC, 577
 - in refractory ovarian cancer, 251-252
 - trials of, in NSCLC, 573-576
- Cisplatin, doxorubicin, cyclophosphamide regimen, for invasive bladder cancer, 625, 627
- Cisplatin, etoposide regimen, as adjuvant therapy
- results of, 644
 - in testis cancer, 644
- Cisplatin, 5-FU regimen, in head and neck cancer, 540
- Cisplatin, 5-FU, etoposide regimen, in gastric cancer, 592-593
- Cisplatin, 5-FU, radiotherapy regimen, in head and neck cancer, 547-548
- Cisplatin, methotrexate, vinblastine regimen, for invasive bladder cancer, 625, 627
- Cisplatin, vinblastine, bleomycin regimen, as adjuvant therapy, 642-643
- Classification
- CPV, of choriocarcinoma, 104
 - Elston, 104
 - FIGO, of gestational trophoblastic disease, 145, 174
 - Hertig system of, 101
 - NIH, of gestational trophoblastic disease, 146
- Clomipramine, as chemosensitizing agent, 23
- Clone(s)
- chromosomally abnormal, origin of, 343
 - multiple, 343-344
 - sub-, 343
- C-myc protein, functional map of, 215
- c-myc oncogene, in colorectal cancer, 423-424
- Colectomy, prophylactic, 418
- Colon cancer
- adjuvant immunotherapy in, 605-606
 - adjuvant portal vein chemotherapy in, 604-605
 - adjuvant therapy of, 600-610
 - age in, 440
 - barium enema evaluation in, 439
 - cell proliferation detection in, 442
 - chemoimmunotherapy in, 606
 - colonoscopy screening in, 439
 - fecal occult blood test screening in, 434-435
 - fecal occult blood test trials in, 436-437
 - future screening strategies for, 441-443
 - historic trials in, 601
 - incidence of, 489
 - levamisole plus 5-FU in, 601-602
 - markers for, 442
 - mortality due to, 489
 - multi-institutional adjuvant trials in, 604
 - national screening cost for, 441
 - ornithine decarboxylase detection in, 442-443
 - positive family history in, screening and, 440-441
 - postoperative irradiation therapy in, 606-607
 - potential prognostic indicators in, 601
 - prognostic factors in, 600

Colon cancer (*Continued*)

- protein kinase-C detection in, 442-443
 - screening for, 433-447
 - screening intervals in, 440
 - screening personnel for, 441
 - screening recommendations in, 435
 - screening strategies in, 439-441
 - sigmoidoscopy screening in, 437-439
 - sporadic, incidence of, 440-441
- Colonoscopy, in colon cancer screening, 439
- Colony stimulating factor, granulocyte, *see* Granulocyte-colony stimulating factor
- Colony-forming units-erythroid, 308
- Colony-forming units-granulocyte-erythroid-macrophage-megakaryocyte, 308
- Colony-forming units-megakaryocyte, 309
- Colony-stimulating factor
 - for chemotherapy toxicity rescue, 518-519
 - granulocyte-macrophage, 308
 - tumor vaccine cells and, 86
- Colorectal cancer
 - adjuvant chemotherapy in, 472-487
 - adjuvant immunotherapy in, 481
 - allelic loss in, 419-422
 - biology of, clinical implications of, 418-432
 - CEA monitoring cost in, 491
 - cellular oncogenes in, 423-424
 - chemotherapeutic targets in, 426-428
 - combination chemotherapy in, 475-476
 - comparative imaging studies in, 464
 - CT in, 457-461
 - cytokeratinic antigen 17-1A in, 425
 - DNA ploidy in, 424-425
 - endoluminal ultrasound in, 452-456
 - endosonographic staging in, 453-455
 - failure patterns in, 473-474
 - follow-up in, cost of, 492
 - 5-FU, levamisole regimen in, 427-428
 - 5-FU biochemical modulation in, 509-524
 - genetic model for, 419
 - genomic instability in, 422-423
 - hepatic-directed therapy in, 494-508
 - hereditary factors in, 418-419
 - hereditary nonpolyposis, 418-419
 - incidence of, 418
 - intraoperative ultrasound in, 456-457
 - irinotecan in, 516
 - leucovorin, 5-FU regimen in, 480-481
 - levamisole, 5-FU regimen in, 479
 - levamisole adjuvant therapy in, 477-480
 - meta-analysis in, 490-492
 - metastatic disease detection in, 494-495
 - metastatic survival in, 494
 - methyl lomustine, 5-FU, vincristine regimen in, 427-428
 - MRI detection of, 458-459
 - MRI in, 457-462
 - MRI staging of, 458-459
 - mucins in, 426
 - new imaging techniques in, 448-471
 - ongoing adjuvant trials in, 482-483
 - PET in, 462-466

Colorectal cancer (*Continued*)

- portal vein therapy in, 476-477
 - postoperative evaluation in, 488-493
 - prognostic factors in, 472-473
 - radioimmunodetection of, 448-451
 - radioimmunodetection trials in, 449-451
 - recent advances in, 415-417
 - recurrent
 - curative therapy for, 489-490
 - endosonographic evaluation of, 455-456
 - MRI detection of, 459-461
 - PET imaging in, 464-465
 - regional chemotherapy in, 501
 - screening for, 433-447
 - single agent adjuvant therapy in, 474-475
 - sporadic nonfamilial, 419-422
 - staging of, 472-473
 - systemic chemotherapy in, 500
 - time trend analysis in, 490
 - tumor associated antigens in, 425-426
 - tumor suppressor genes in, 419-422
- Combination chemotherapy
 - in high-grade astrocytoma, 533
 - in NSCLC, 579
 - radiotherapy plus
 - in head and neck cancer, 545-547
 - randomized trials of, 546
- Combined modality therapy
 - adjuvant, in esophageal cancer, 587-590
 - in head and neck cancer, 548
- Complementary determining regions, 448
- Complete response, definition of, 42
- Computed tomography
 - in colorectal cancer, 457-461
 - in gestational trophoblastic disease, 134
 - portography, for liver metastasis detection, 494
- Conceptus, examination of, methods of, 117-118
- Contig, definition of, 4
- Corynebacterium parvum*, for melanoma, 652-653
- Cost
 - of CEA monitoring, in colorectal cancer, 491
 - of colorectal cancer follow-up, 492
 - of national colon cancer screening, 441
- Cost effectiveness, of high-dose chemotherapy, 244-245
- COU-1, in radioimmunodetection, 451
- Coumarin, cimetidine plus, in renal cell cancer, 44
- Counterflow centrifugal elutriation, 212
- CPT-11, 516
- CPV classification, of choriocarcinoma, 104
- C-reactive protein, plasma levels of, in reactive thrombocytosis, 336
- Cryopreservation, of stem cells, complications of, 264, 268-269
- Cryosurgery, for hepatic metastases, 503-504
- Cryotherapy, in chemotherapy rescue, 519
- CT, *see* Computed tomography
- Cutaneous melanoma, *see* Melanoma, cutaneous
- Cyclophosphamide, 177, 655
 - in chemoradiotherapy, for NSCLC, 578
 - cytarabine plus-, 220
 - etoposide plus-, 220
 - dose intensity of, in breast cancer, 561-563

- Cyclophosphamide (*Continued*)
 dose sequencing of, in breast cancer, 563-564
 in gestational trophoblastic disease, 147
 high-dose, in multiple myeloma, 230
 in high-dose combination regimen, for ovarian cancer, 256-257
 in matched sibling BMT, for chronic myelogenous leukemia, 406
 in mobilization, 258
 misondazole plus, in renal cell cancer, 44
 in peripheral blood progenitor cell transplantation, for multiple myeloma, 233
 postoperative, in gastric cancer, 590-592
 in prostate cancer, 637
 randomized trials of, in NSCLC, 577
 trials of, in NSCLC, 573-576
 Cyclophosphamide, cisplatin, doxorubicin regimen, for invasive bladder cancer, 625, 627
 Cyclophosphamide, doxorubicin, 5-FU regimen, in breast cancer, 238-240
 Cyclophosphamide, doxorubicin, vincristine, dexamethasone regimen, in CNS lymphomas, 537
 Cyclophosphamide, doxorubicin, vincristine, prednisone regimen, in CNS lymphomas, 537
 Cyclophosphamide, etoposide, cytarabine, regimen, high-dose, 220
 Cyclophosphamide, methotrexate, 5-FU regimen
 in breast cancer, 238-240, 553
 in chemohormonal therapy, for breast cancer, 557
 Cyclophosphamide, methotrexate, procarbazine regimen, intra-arterial, in astrocytoma, 535
 Cyclosporine A
 as chemosensitizing agent, 23
 vinblastine plus, in renal cell cancer, 50
 Cystitis, hemorrhagic, due to stem cell harvesting, 264
 Cytarabine, 594
 in chronic myelogenous leukemia, 398
 in high-dose therapy regimen, 220
 postoperative, in gastric cancer, 590-592
 Cytogenetic abnormalities, in polycythemia rubra vera, 313
 Cytokeratin antigen
 17-1A, 425
 in colorectal cancer, 425-426
 Cytokine(s)
 in chemotherapy toxicity rescue, 519
 delivery of, 14
 genes encoding, in tumor cells, 83-84
 Cytosan, *see* Cyclophosphamide

 Dacarbazine
 for melanoma, 650-652, 654
 in adjuvant therapy, 647-649
 Dactinomycin, 177
 in gestational trophoblastic disease, 147
 10-Deaza-aminopterin, in renal cell cancer, 45
 del(12)(p12), in myeloproliferative disorders, 341, 342
 del(13)(q12q14), in myeloproliferative disorders, 341, 342, 348-349
 del(20)(q11), 350-351
 in myeloproliferative disorders, 341, 342
 del(5)(q13q33), in myeloproliferative disorders, 341, 342

 Deleted in colon cancer gene, location of, 420-421
 Density gradient centrifugation, 212
 Deoxycorformycin, in renal cell cancer, 45
 Designer drug, for thymidylate synthase inhibition, 515
 Dexamethasone, vincristine, doxorubicin regimen, in chronic myelogenous leukemia, 400-401
 Dexamethasone, cyclophosphamide, doxorubicin, vincristine regimen, in CNS lymphomas, 537
 Diaminocyclohexane platinum complex, 517
 Diaziquone, 533
 in renal cell cancer, 45
 Didemnin-B, in renal cell cancer, 45
 Diltiazem, as chemosensitizing agent, 23
 Dinitrochlorobenzene, pre- ν postoperative, for melanoma, 652
 Dinitrophenyl, 655
 Dinucleotide repeat, in colorectal cancer, 422
 Diploidy, diandric, 114-115
 Dipyridamole
 in polycythemia rubra vera, 316
 vinblastine plus, 50
 DNA
 methylation of, in colorectal cancer, 421
 tumor, phenotype in, 422-423
 DNA binding domain, 215
 DNA ploidy
 in colorectal cancer, 424-425
 in head and neck cancer, 549
 as prognostic factor, in colorectal cancer, 473
 DNA probe, with fluorescence in situ hybridization, 341
 Doppler ultrasound, in gestational trophoblastic disease, 133-134
 Dose intensity, of chemotherapy, in ovarian cancer, 250-251
 Doxifluridine, 513-514
 Doxorubicin
 in adjuvant therapy, for breast cancer, 553-554
 dose intensity of, in breast cancer, 561-563
 dose sequencing of, in breast cancer, 563-564
 in gestational trophoblastic disease, 147
 for invasive bladder cancer, 625, 627
 postoperative, in gastric cancer, 590-592
 trials of, in NSCLC, 573-576
 vinblastine plus, in renal cell cancer, 50
 Doxorubicin, cisplatin, cyclophosphamide regimen, for invasive bladder cancer, 625, 627
 Doxorubicin, cyclophosphamide, 5-FU regimen, in breast cancer, 238-240
 Doxorubicin, cyclophosphamide, vincristine, dexamethasone regimen, in CNS lymphomas, 537
 Doxorubicin, cyclophosphamide, vincristine, prednisone regimen, in CNS lymphomas, 537
 Doxorubicin, methotrexate, 5-FU regimen, in gastric cancer, 593
 Doxorubicin, methotrexate, vinblastine regimen, for invasive bladder cancer, 625, 627
 Doxorubicin, vincristine, dexamethasone regimen, in chronic myelogenous leukemia, 400-401
 DTIC, *see* Dacarbazine
 Duke's stage, of colorectal cancer, DNA ploidy and, 424-425

 Echinomycin, in renal cell cancer, 45
 Elliptinium, in renal cell cancer, 45

- Elston classification, of choriocarcinoma, 104
- Endoluminal ultrasound
- in colorectal cancer, 452-456
 - future colorectal applications of, 456
 - for lymph node assessment, 455
 - in sphincter-saving surgery, 455
- Endosonography, *see* Endoluminal ultrasound
- Enzyme-linked immunosorbent assay, of human chorionic gonadotropin, 125-126
- Ependymoma
- adjuvant therapy of, 536-537
 - neoadjuvant therapy of, 536-537
- Epidermal growth factor receptor, in head and neck cancer, 549
- Epirubicin
- dose intensity of, in breast cancer, 562-563
 - in neoadjuvant therapy, for head and neck cancer, 541
 - in renal cell cancer, 45
- Epithelial growth factor, in chemotherapy rescue, 519
- Epithelial membrane antigen, radioimmunodetection of, 448
- Erythrocytosis
- in polycythemia rubra vera diagnosis, 312
 - secondary, erythropoietin levels in, 308
- Erythroleukemia, 392
- Erythromelalgia, in polycythemia rubra vera, 312
- Erythropoietin
- in secondary erythrocytosis, 308
 - normal levels of, 308
 - secretion of, in polycythemia rubra vera, 307-308
- Erythropoietin receptor, in polycythemia rubra vera, 310
- Esophageal cancer
- adjuvant combined modality therapy in, 587-590
 - adjuvant therapy in, 582-599
 - chemoradiotherapy in, 584-585
 - failure pattern in, 582-584
 - incidence of, 582
 - neoadjuvant therapy of, 584
 - patient selection in, 585-586
 - postoperative chemotherapy in, 586-587
 - resection in, survival following, 585
 - surgery in, 586-587
- Esophagectomy, transhiatal, in esophageal cancer, 586
- Esoresubin, in renal cell cancer, 45
- Essential thrombocythemia
- cytogenetics of, 349
 - definition of, 349
 - diagnosis of, 335
 - diagnostic criteria for, 335, 364
 - differential diagnosis of, 366-367
 - evolution of, 366
 - major features of, 368
 - morphologic findings in, 364-366
 - pathogenesis of, 334-335
 - pregnancy and, 338-339
 - prognosis in, 336-3337
 - reactive thrombocytosis *v.*, 335
 - treatment of, 337-338
 - in young patients, 338
- Estramustine phosphate, in prostate cancer, 637
- Ethanol, percutaneous injection therapy with, for hepatic metastases, 504
- Ethynyluracil, in 5-FU biochemical modulation, 514
- Etoposide
- in gestational trophoblastic disease, 147
 - in high-dose combination regimen, 220, 256-257
 - in matched sibling BMT, for chronic myelogenous leukemia, 406
 - in mobilization, 258
 - for ovarian cancer, 256-257
 - in peripheral blood progenitor cell transplantation, for multiple myeloma, 233
 - randomized trials of, in NSCLC, 577
- Etoposide, cisplatin regimen, as adjuvant therapy, in testis cancer, 644
- Etoposide, cisplatin, 5-FU regimen, in gastric cancer, 592-593
- Europium, 126
- Familial adenomatous polyposis, hereditary factors in, 418-419
- Family history, in colon cancer screening, 440-441
- FDG, in PET imaging, 463
- Fecal occult blood test
- in average risk persons, 436-437
 - in colon cancer, 434-435
 - controlled trials of, 436
 - false-negative, causes of, 435
 - false-positive, causes of, 435
- Fetal pole, 98
- Fibroblast, for gene therapy, 14
- Fibroblast activation protein, radioimmunodetection of, 448
- FIGO staging, 174
- of gestational trophoblastic disease, 145
- Flavone-8-acetic acid, 10
- Flavonoids, definition of, 10
- Flow cytometry
- in gestational trophoblastic disease, 106
 - in stem cell tumor detection, 273
- Floxuridine
- folinic acid plus, 46
 - interferon plus, 46
 - postoperative, in gastric cancer, 590-592
 - vinblastine plus, 46
- Floxuridine, folinic acid, interferon regimen, in renal cell cancer, 46
- Fludarabine, in renal cell cancer, 46-47
- Flunarizine, as chemosensitizing agent, 23
- Fluorescence in situ hybridization, DNA probe with, 341
- Fluorodeoxyglucose, in PET imaging, 463-464
- Fluorouracil
- in adjuvant therapy, for breast cancer, 553-554
 - biochemical modulation of, in metastatic colorectal cancer, 509-524
 - biochemical modulation trials of, 512
 - bolus *v.* protracted venous infusion of, in rectal cancer, 615
 - in chemoradiotherapy
 - for head and neck cancer, 546-547
 - for rectal cancer, 614 - in colorectal cancer, 426-428, 474-475, 479
 - dose intensity of, in breast cancer, 561-563
 - dose sequencing of, in breast cancer, 563-564
 - folinic acid plus, 47
 - history of, 509
 - interferon plus, 47
 - for invasive bladder cancer, 625, 627

- Fluorouracil (*Continued*)
 interferon-alpha biochemical modulation of, 511-513
 leucovorin biochemical modulation of, 509-511
 leucovorin plus, in colorectal cancer, 480-481
 metabolic pathways of, 510
 in neoadjuvant therapy, for head and neck cancer, 541
 in neoadjuvant trials, for head and neck cancer, 542-543
 PALA biochemical modulation of, 511
 postoperative, in gastric cancer, 590-592
 prodrugs of, 513-514
 in prostate cancer, 638
 semustine plus, in colorectal cancer, 475
 uracil plus, 47
- Fluorouracil, cisplatin regimen, in head and neck cancer, 540
- Fluorouracil, cisplatin, etoposide regimen, in gastric cancer, 592-593
- Fluorouracil, cisplatin, radiotherapy regimen, in head and neck cancer, 547-548
- Fluorouracil, cyclophosphamide, doxorubicin regimen, in breast cancer, 238-240
- Fluorouracil, cyclophosphamide, methotrexate regimen in breast cancer, 553
 dose intensity of, 238-240
- Fluorouracil, folinic acid regimen, adjuvant, trials of, 602-604
- Fluorouracil, folinic acid, levamisole regimen, adjuvant, trials of, 604
- Fluorouracil, methotrexate, doxorubicin regimen, in gastric cancer, 593
- Flutamide, interferon plus, in renal cell cancer, 47
- Folinic acid
 in adjuvant chemotherapy, for colorectal cancer, 474-475
 in chemoradiotherapy, for rectal cancer, 617-618
 floxuridine plus, in renal cell cancer, 46
 ftorafur plus, 513
 in 5-FU biochemical modulation, 509-511
 in gestational trophoblastic disease, 147
 high-dose trials of, in breast cancer, 563
 mechanism of action of, 427
 in neoadjuvant therapy
 for colorectal cancer, 474-475
 for head and neck cancer, 541
- Folinic acid, floxuridine, interferon regimen, in renal cell cancer, 46
- Folinic acid, fluorouracil regimen
 adjuvant, trials of, 602-604
 in colorectal cancer, 480-481
 in renal cell cancer, 47
- Folinic acid, fluorouracil, levamisole regimen, adjuvant, trials of, 604
- Fosquidone, in renal cell cancer, 47
- Fotemustine, in renal cell cancer, 47
- Ftorafur
 development of, 513
 postoperative, in gastric cancer, 590-592
- 5-FU, see Fluorouracil
- G-protein, 419-420
- Gallium nitrate
 for invasive bladder cancer, 625
 in renal cell cancer, 47
- GAP, 214
- Gardener's syndrome, hereditary factors in, 418-419
- Gastric cancer
 adjuvant therapy in, 582-599
 chemoradiotherapy in, 584-585, 593
 failure pattern in, 582-584
 immunochemotherapy in, 593-594
 incidence of, 582
 intraperitoneal chemotherapy in, 594-595
 neoadjuvant therapy in, 584, 592-593
 patient selection in, 585-586
 postoperative chemotherapy in, 586-587, 590-592
 resection in, survival following, 585
 surgery in, 586-587
- GATA-1, 215
- Gemcitabine, in renal cell cancer, 47
- Gene(s)
 for drug sensitivity, 282
 mismatch repair, 419
- Gene therapy, 281-283
 for renal cell cancer, 81-91
 methods of, 279-280
- Germ cell tumor, cure of, 641
- Gestational trophoblastic disease
 biologic processes of, 96
 chemotherapy in, 147
 CNS metastasis of, 137-139
 CT of, 134
 definition of, 96
 diagnosis of, 172-173
 DNA content in, 143
 Doppler sonography of, 133-134
 epidemiology of, 109-113
 FIGO staging of, 145
 flow cytometry in, 106
 genetic analysis of, 113-120
 HCG levels in, 144-147
 hepatic metastasis of, 137
 high-risk, see High-risk gestational trophoblastic disease
 histogram in, 143
 histopathology of, 142-143
 imaging of, 130-141
 immunocytochemistry in, 106
 infertility following, 196
 karyotyping in, 106
 malignant, see Malignant gestational trophoblastic disease
 metastatic, whole brain radiation therapy for, 185-190
 metastatic sites of, 137
 MRI of, 134-135
 NIH classification of, 146
 nonmetastatic complications of, 139
 nonvillous, 116-117
 nuclear medicine in, 135-136
 overview of, 95
 pathology of, 96-109
 persistent, reproduction following, 194-195
 ploidy analysis in, 106
 prognostic variables in, 142-148
 pulmonary metastasis of, 136-137
 recurrent, 182

- Gestational trophoblastic disease (*Continued*)
 reproduction following, 193-197
 sonography of, 130-133
 staging of, 142-148
 steroids for, 187
 therapy of, infertility following, 196
 vaginal metastasis of, 139
 villous, 113-116
 WHO prognostic index score for, 146
- Glioma, astrocytoma-type of, 531-532
- Glutaraldehyde, 456
- Graft, IL-7 and, 112
- Graft engineering, 277-278
- Granulocyte-colony stimulating factor
 in breast cancer, 562
 for chemotherapy rescue, 518-519
- Granulocyte-macrophage colony-stimulating factor, 308
 for chemotherapy rescue, 518-519
 tumor vaccine cells and, 86
- Growth factor(s)
 in chemotherapy rescue, 519
 identification of, 204
- Harvesting, see Stem cell harvesting
- HCG, see Human chorionic gonadotropin
- HD, see Hodgkin's disease
- Head and neck cancer
 adjuvant therapy in, 540-552
 chemoradiotherapy in, 545-548
 chemotherapy alternating with radiotherapy in, 547
 chemotherapy following radiotherapy in, 547
 cisplatin, 5-FU regimen in, 540
 cisplatin, 5-FU, radiotherapy regimen in, 546-548
 combined modality therapy in, 548
 neoadjuvant therapy in, 540-552
 new prognostic indicators for, 549
 organ preservation in, 543-545
 prognostic subgroups in, 548-549
- Hematopoietic stem cell(s)
 asynchronous division of, 210-211
 biology of, 210-217
 cytokines and, 213-214
 development of, extracellular regulation of, 213
 developmental biology of, 212-216
 division of, 212-213
 immunocytochemical isolation of, 211-212
 isolation of, 211-212
 peripheral blood circulation of, 216
 physical isolation of, 212
 stochastic differentiation of, 213
 sub-cellular events and, 214-216
- Hemorrhage, in polycythemia rubra vera, 312
- Hemorrhagic cystitis, due to stem cell harvesting, 264
- Hepatic artery embolization, for hepatic metastases, 503
- Hepatic artery infusion
 in colorectal cancer, 501-503
 toxicities of, 502-503
 trials of, 502
- Hepatic artery ligation, for hepatic metastases, 503
- Hepatic metastasis, PET imaging of, in colorectal cancer, 465-466
- Hepatic resection
 complications of, 497
 hepatic anatomic segments in, 495, 496
 margins in, 498
 in metastatic colorectal cancer, 495-500
 recurrence following, 499
 repeat, results of, 500
 total vascular isolation in, 497
- Hepatic-directed therapy, in colorectal cancer, 494-508
- Hepatocellular cancer, percutaneous ethanol injection therapy in, 504
- Hereditary nonpolyposis colorectal cancer, hereditary factors in, 418-419
- Hertig grading system, 101
- HHT, in chronic myelogenous leukemia, 400-401
- High-dose chemotherapy
 as conditioning regimen, complications of, 264, 265-268
 cost-effectiveness of, 244-245
 future directions in, 245-246
 hematopoietic progenitor cell support and, in ovarian cancer, 250-262
 intraperitoneal, 252-253
 multiple sequential, hematopoietic progenitor cell support for, 257-258
 in newly diagnosed ovarian cancer, 256-257
 quality of life following, 244
 rationale for, 205
 toxicities of, 243-244
 trials of, in breast cancer, 563
- High-risk gestational trophoblastic disease, 172-184
 combination chemotherapy in, 178
 drug-resistant, 180-181
 surgery for, 181
 therapy monitoring in, 181-182
 treatment of, 177-182
 triple-agent chemotherapy in, 177
 weekly chemotherapy in, 178
- Hodgkin's disease
 autologous marrow reinfusion regimens in, 224-226
 marrow fibrosis in, 369
- Homing mechanism, of stem cells, 278
- Hormonal therapy
 adjuvant, in breast cancer, 555-556
 chemotherapy plus, in breast cancer, 556-558
 in adjuvant therapy, for melanoma, 649
- Hormones, in renal cell cancer, 52
- Human chorionic gonadotropin
 alpha subunit of, 122
 beta subunit of, 122
 biological properties of, 122-123
 carbohydrate moieties of, 121-122
 carbohydrate role in, 123
 immunoradiometric assay of, 125
 levels of, in gestational trophoblastic disease, 144
 molecule of, 121-122
 nonradioisotopic measurement of, 125-126
 quantitative measurement of, 123-126
 radioimmunoassay of, 123-125
 receptor binding of, 123
 reference preparations of, 126-127
 subunit structure of, 121

- Human placental lactogen, 104
- Hydatidiform mole
 chemoprophylaxis of, 157-160
 contraception and, 153-154
 diagnostic studies of, 149-150
 early, 98
 follow-up of, 153, 154
 management of, 151-153
 nonneoplastic complications of, 150-151
 prophylactic chemotherapy for, reproduction following, 195
 symptoms of, 149
 treatment of, indications for, 154
- Hydroxyurea
 in adjuvant therapy, for melanoma, 647-649
 in chronic granulocytic leukemia, 387-388
 in chronic myelogenous leukemia, 396-397
 in essential thrombocythemia, 337
 in gestational trophoblastic disease, 147
 in polycythemia rubra vera, 316-317
 prior to interferon alpha therapy, 399
- Hypereosinophilic syndrome, 362
- Hyperproliferation, in colon cancer, 442
- Hypocalcemia, due to stem cell harvesting, 265
- Hypotension, due to stem cell harvesting, 265
- ICRF-187, in renal cell cancer, 47
- Idarubicin, in renal cell cancer, 47
- Ifosfamide
 for invasive bladder cancer, 625
 randomized trials of, in NSCLC, 577
 with or without mesna, in renal cell cancer, 47
- IGF-1, 214
- IL, *see* Interleukin
- Imaging, new techniques of, in colorectal cancer, 448-471
- Immunization, active specific, for melanoma, 653-654
- Immunotherapy, in gastric cancer, 593-594
- Immunocytochemistry, in gestational trophoblastic disease, 106
- Immunofluorometric assay, of human chorionic gonadotropin, 126
- Immunohistochemical marker, in head and neck cancer, 549
- Immunological agents, in renal cell cancer, 53-54
- Immunomodulation, 278-279
- Immunopotential, for melanoma, 654-655
- Immunoradiometric assay, of human chorionic gonadotropin, 125
- Immunotherapy
 adjuvant, in colorectal cancer, 481
 adoptive, IL-7 plus, 13
 for melanoma, 650-653
 genetically modified cell-based, rationale for, 81-82
 surgery plus, in renal cell cancer, 31-32
 with cytokeratinic antigen 17-1A, 425
- Indium, radiolabeled, for imaging, 449
- Inferior vena cava, in renal cell cancer, 30-31
- Intercalating agents, in renal cell cancer, 53
- Interferon
 cimetidine plus, 44
 in combination regimens, 54
 in essential thrombocythemia, 338
 floxuridine plus, 46
 flutamide plus, 47
- Interferon (*Continued*)
 5-FU plus, 47
 for melanoma, 649-650
 in neoadjuvant therapy, for head and neck cancer, 541
- Interferon- α , in polycythemia rubra vera, 318
- Interferon alpha, 309
 in chronic granulocytic leukemia, 387-388
 in chronic myelogenous leukemia, 396-397, 398
 in 5-FU biochemical modulation, 511-513
 low-dose IL-2 plus, 69-70
 response to, in chronic myelogenous leukemia, 400
 therapy with, guidelines for, 399-400
- Interferon, floxuridine, folinic acid regimen, in renal cell cancer, 46
- Interleukin, stem cell growth and, 213-214
- Interleukin-2
 in chemotherapy toxicity rescue, 519
 equivalent doses of, 68
 high-dose
 LAK cells with, 63-64
 regimen with, 61
 in renal cell cancer, 61-66
 standard dose v, 64-65
 therapy results with, 63
 toxicity of, 61-63
 use of, 65
 LAK cells plus, phase II trials of, 76
 low-dose
 immunological effects of, 67-68
 interferon alpha plus, 69-70
 monotherapy with, 68-69
 other agents plus, 69-71
 in renal cell cancer, 67-73
 tumor-infiltrating lymphocytes plus, 279
 phase I- II trials of, 77
 UCLA trials of, 78
- Interleukin-3, 309
- Interleukin-6, plasma levels of, in reactive thrombocytosis, 336
- Interleukin-7
 adoptive immunotherapy plus, 13
 antitumor effects of, 11-12, 13
 engraftment and, 112
 immunomodulatory effects of, 10-12
- International reference standard, for human chorionic gonadotropin, 126-127
- Intraepithelial lymphocyte, 11
- Intraoperative ultrasound
 for liver metastasis detection, 495
 in colorectal cancer, 456-457
- Intraperitoneal therapy, high-dose, in ovarian cancer, 252-253
- Invasive hydatidiform mole
 MRI of, 136
 pulmonary metastasis of, 137
 sonography of, 133, 134
- Iodine, radiolabeled, for imaging, 449
- Irinotecan, in colorectal cancer, 516
- Iscador, in renal cell cancer, 48
- K-ras gene, in colorectal cancer, 423-424
- K-ras mutation
 frequency of, 420
 in colorectal cancer, 419

- Karyotyping, in gestational trophoblastic disease, 106
53-Kd nuclear protein, 420
Kit ligand, stem cell growth and, 213-214
KL receptor, 214
Krigel, MD, Robert L, in memoriam, 201
- Laboratory values, in polycythemia rubra vera, 311
LAK cells, *see* Lymphokine activated killer cell(s)
Lead time bias, in colon cancer, 434
Length bias, in colon cancer, 434
Leucine zipper, 215
Leucovorin, *see* Folinic acid
Leukemia
 acute, in polycythemia rubra vera, 314, 363-364
 chronic basophilic, 381
 chronic eosinophilic, 381
 chronic myeloid types of, 381
 following chlorambucil, 314
 juvenile chronic myeloid, 381
 Ph-positive acute, 361
 terminology in, 380
Leukocyte-conditioned medium, 308
Leukoerythroblastosis, 367
Leukopenia, following high-dose conditioning regimen, 266
Levamisole, 5-FU regimen
 in adjuvant therapy, for melanoma, 647-649
 in chemoradiotherapy, for rectal cancer, 617-618
 in colon cancer, 605-606
 in colorectal cancer, 426-428, 477-480
 in combination chemotherapy, for breast cancer, 239
 for melanoma, 650-651
 in NSCLC, 573-576
 trials of, 478-480
Liver
 anatomic segments of, in hepatic resection, 495, 496
 assessment of, in metastatic colorectal cancer, 494-495
 gestational trophoblastic disease metastatic to, 137
 intraoperative ultrasound of, 457
 metastasis to, 179-180
 radiation therapy for, 188-190
 resection of, *see* Hepatic resection
Liver function test, for metastasis detection, 495
Lomustine
 amphotericin B plus, in renal cell cancer, 48
 in chemoradiotherapy
 for NSCLC, 578
 for rectal cancer, 614
 for melanoma, 651
 postoperative, in gastric cancer, 590-592
 value of, in rectal cancer, 616
Lomustine, procarbazine, vincristine regimen, in high-grade astrocytoma, 533
Lomustine, vincristine, 5-FU regimen, in colorectal cancer, 427-428
Long-term colony initiating cell, 203, 210
Lonidamine, in renal cell cancer, 48
L-phenylalanine mustard, in adjuvant chemotherapy, for breast cancer, 553-554
Lung, gestational trophoblastic disease metastatic to, 136-137
Lung cancer
 incidence of, 571
Lung cancer (*Continued*)
 non-small cell
 adjuvant radiotherapy in, 572
 adjuvant therapy in, 572-576
 adjuvant therapy trials in, 573
 chemoradiotherapy in, 578-579
 chemoradiotherapy v radiation in, 578
 neoadjuvant therapy in, 576
 neoadjuvant therapy trials in, 577-578
 new combination chemotherapy regimens in, 579
 perioperative chemotherapy defined in, 571
 perioperative therapy of, 571-581
 single-institution phase II data in, 576-577
 surgery in, 572
Luteinizing hormone-releasing hormone, in breast cancer, 558
Lymph node dissection
 elective, for melanoma, 656-657
 in upper gastrointestinal tract cancers, 586-587
Lymph nodes, endosonographic assessment of, 455
Lymphokine activated killer cell(s)
 adherent, 375
 IL-2 plus, phase II trials of, 76
 in renal cell cancer, 75-76
Lymphoma
 high-dose therapy in, stem cell infusion for, 218-229
 of CNS
 adjuvant therapy of, 536-537
 cyclophosphamide, doxorubicin, vincristine, dexamethasone regimen for, 537
 cyclophosphamide, doxorubicin, vincristine, prednisone regimen for, 537
 neoadjuvant therapy of, 536-537
Mafosfamide
 in renal cell cancer, 48
 in tumor purging, 274
Magnetic resonance imaging
 in colorectal cancer, 457-462
 in gestational trophoblastic disease, 134-135
 future trends in, 461-462
 for liver metastasis detection, 494-495
Major BCR, in chronic granulocytic leukemia, 344
Major BCR-ABL fusion, in chronic granulocytic leukemia, 345
Major histocompatibility complex genes, expression of, 82-83
Malignant gestational trophoblastic disease
 ABO blood type in, 176
 antecedent pregnancy in, 175-176
 classification of, 173-176
 classification systems in, 176
 clinicopathologic diagnosis of, 176
 duration of, 175
 FIGO staging of, 174
 HCG levels in, 175
 metastatic sites in, 175
 modified WHO prognostic index score for, 174
 nonmetastatic, 174-175
 prior chemotherapy in, 176
Marker(s)
 candidate, in colon cancer, 443
 in colon cancer screening, 442

- MDR 1 gene, 282
 in clinical trials, 24-26
 in-gel renaturation for, 17
 localization of, 19
- MDR 2 gene, in-gel renaturation for, 17
- Medulloblastoma
 adjuvant therapy of, 536-537
 neoadjuvant therapy of, 536-537
- Megakaryocyte-platelet-derived growth factor, in bone marrow fibrosis, 328
- Megestrol acetate, for melanoma, 649
- Melanoma, cutaneous
 active specific immunization for, 653-654
 adjuvant radiotherapy for, 657
 adjuvant therapy for, 647-661
 antigen-supplemented whole tumor cells for, 655
 bacille Calmette-Guerin for, 650-652
 Corynebacterium parvum for, 652-653
 elective lymph node dissection for, 656-657
 hormonal therapy for, 649
 immunopotentialization for, 654-655
 incidence of, 647
 interferon for, 649-650
 levamisole for, 650-651
 megestrol acetate for, 649
 nonspecific immunotherapy for, 650-653
 nonsystemic adjuvant therapy for, 656-657
 vaccines for, 653-655
 vitamin A for, 656
- Melphalan
 high-dose, in multiple myeloma, 230
 in high-dose combination regimen, for ovarian cancer, 256-257
 mitoguazone plus, in renal cell cancer, 48
 in peripheral blood progenitor cell transplantation, 233
 prednisone plus, in multiple myeloma, 230
 in renal cell cancer, 48
- Melphalan, carmustine, cytarabine regimen, high-dose, 220
- Menogril, in renal cell cancer, 48
- Merocyanine 540, 275-276
- Mesna, ifosfamide plus, in renal cell cancer, 47
- Metals, in renal cell cancer, 52
- Methotrexate
 dose intensity of, in breast cancer, 561-563, 563
 dose sequencing of, in breast cancer, 563-564
 dosing of, in complete molar pregnancy, 159
 in gestational trophoblastic disease, 147, 177
 high-dose trials of, in breast cancer, 563
 for invasive bladder cancer, 625, 627
 postoperative, in gastric cancer, 590-592
- Methotrexate, 5-FU, doxorubicin regimen, in gastric cancer, 593
- Methotrexate, cisplatin, vinblastine regimen, for invasive bladder cancer, 625, 627
- Methotrexate, cyclophosphamide, 5-FU regimen, in breast cancer, 238-240, 553
- Methotrexate, procarbazine, cyclophosphamide regimen, intra-arterial, in astrocytoma, 535
- Methotrexate, vinblastine, doxorubicin regimen, for invasive bladder cancer, 625, 627
- Methyl lomustine, 5-FU, vincristine regimen, in colorectal cancer, 427-428
- Methylation, DNA, in colorectal cancer, 421
- N-Methylformamide, in renal cell cancer, 48
- Microsatellite, definition of, 422
- Minor BCR, in chronic granulocytic leukemia, 344
- Minor response, definition of, 42
- Misonidazole, cyclophosphamide plus, in renal cell cancer, 44-45
- Missense mutation, 420
- Mitoguazone
 in renal cell cancer, 48
 melphalan plus, 48
- Mitolactol, in renal cell cancer, 48
- Mitolozomide, in renal cell cancer, 48
- Mitomycin C, 594
 in chemoradiotherapy, for head and neck cancer, 546-547
 in neoadjuvant trials, for head and neck cancer, 542-543
 postoperative, in gastric cancer, 590-592
 randomized trials of, in NSCLC, 577
- Mitoxantrone, in renal cell cancer, 48
- MLH-1 gene, 419
 in colorectal cancer, 422
- Mobilization, of stem cells, complications of, 263-265
- Modulating agents, in renal cell cancer, 53
- Molar pregnancy
 chemoprophylaxis in, 157-160
 complete, definition of, 96
 diagnostic problems in, 102
 differential diagnosis of, 97
 implantation site in, 101-102
 partial, definition of, 96, 98-100
 pathologic features of, 96-103
 prognostic factors in, 100-102
 repeat, incidence of, 195
 reproduction following, 194, 195
- Monoclonal antibody(ies)
 availability of, for radioimmunodetection, 448
 in colon cancer, 606
 radiolabeled, clinical experience with, 36-37
 reactive, with renal cell carcinoma, 34-35
- Monoclonal antibody C219, 21
- Monoclonal antibody G250
 chimerized, 37
 for anti-idiotypic antibodies, 37-40
 mediated therapy, 35-36
 in renal cell cancer, 34-41
- Monoclonal antibody H241, 21
- Monoclonal antibody MRK16, 26
- Monosomy 7, 351
- Mouse, severe combined immunodeficiency, engraftment in, 12
- MRI, see Magnetic resonance imaging
- MSH-2 gene, 419
 in colorectal cancer, 422
- Mucin, in colorectal cancer, 426
- Multidrug resistant associated protein, 17, 18
- Multiple drug resistance
 description of, 17-18
 inhibition of, 22-24
 in renal-cell carcinoma, 19-22

- Multiple myeloma
 - allogeneic marrow transplant data in, 231-232
 - blood progenitor cell transplantation in, 232-234
 - dose intensity without stem cell rescue in, 230
 - peripheral blood myeloma cells in, 234
 - transplantation in, 230-237
- Mutated in colon cancer gene, 418
 - location of, 419-420
- Mutator phenotype, in colorectal cancer, 422-423
- Myelofibrosis, in chronic granulocytic leukemia metamorphosis, 392
- Myeloproliferative disorder
 - chromosome abnormalities in, 341-354
 - chronic, 327
 - hematopathologic findings in, 355-373
 - introduction to, 305-306
 - nonspecific, 349-350
 - nonspecific chromosome abnormalities in, 350-351
- Nasopharyngeal cancer, neoadjuvant pilot trials in, 541-542
- National Marrow Donor Program, 407
- Navelbine, in renal cell cancer, 48
- Neoadjuvant chemotherapy
 - adjuvant v. for invasive bladder cancer, 629-630
 - in CNS lymphoma, 536
 - disadvantages of, 534-535
 - in ependymoma, 536
 - in esophageal cancer, 584
 - in gastric cancer, 584, 592-593
 - in head and neck cancer, 540-552
 - for organ preservation, 543-545
 - pilot trials of, 541-542
 - randomized trials of, 542-543
 - survival following, 540-541
 - in high-grade astrocytomas, 535-536
 - for invasive bladder cancer, 625-632
 - in medulloblastoma, 536
 - in NSCLC, 571-581
 - for organ preservation, in head and neck cancer, 543-545
 - overview of, 529, 530-539
 - in pancreatic cancer, 584
 - in prostate cancer, 634
 - randomized trials of, in NSCLC, 577-578
 - strategies of, 534
- Nephrectomy
 - adjuvant, 31
 - immunotherapy plus, 31-32
 - radical, 29
- Network theory, 38
- Neural cell adhesion protein, 421
- Neutropenia
 - following high-dose conditioning regimen, 265-268
 - post-transplant, 267
- Neutrophil alkaline phosphatase score, 380
 - in chronic granulocytic leukemia, 386, 393
- Neutrophils, engraftment rates of, 266
- Nifedipine
 - as chemosensitizing agent, 23
 - vinblastine plus, 50
- NIH classification, of gestational trophoblastic disease, 146
- Nimodipine, as chemosensitizing agent, 23
- Nitredipine, as chemosensitizing agent, 23
- Nitrosourea, in high-grade astrocytoma, 533
- Non-Hodgkin's lymphoma
 - autologous stem cell transplantation in, mortality following, 222
 - PBSC reinfusion in, 221-223
 - relapsed, autologous bone marrow regimens in, 219-221
 - stem cell transplant timing in, 219
 - total body irradiation in, 220-221
- N-phosphonacetyl-L-aspartic acid, in 5-FU biochemical modulation, 511
- N-ras gene, 214
 - in colorectal cancer, 423-424
- NSCLC, *see* Lung cancer, non-small cell
- Nuclear medicine, in gestational trophoblastic disease, 135-136
- Octreotide, 517-518
- OK432, 594
- Oncogene(s)
 - in colorectal cancer, 423-424
 - p53, 420
- Organ preservation, neoadjuvant therapy for, in head and neck cancer, 543-545
- Ornithine decarboxylase, detection of, in colon cancer, 442-443
- Ovarian ablation, in breast cancer, 558-559
- Ovarian cancer
 - chemotherapy dose intensity in, 250-251
 - epithelial, chemotherapy resistance in, 250
 - hematopoietic progenitor cell support in, 252-262
 - marrow contamination in, 259
 - newly diagnosed, high-dose chemotherapy in, 256-257
 - refractory, cisplatin in, 251-252
 - sensitive epithelial, high-dose chemotherapy in, 253-254
- Oxaliplatin, 517
- P* exotoxin, 26
- p53
 - in bladder cancer, 630-631
 - in colorectal cancer, 420
 - in head and neck cancer, 549
 - overexpression of, clinical significance of, 421
 - wild-type, 420
- Paclitaxel
 - dose intensity of, in breast cancer, 562-563
 - for invasive bladder cancer, 625
 - in mobilization, 258
 - in renal cell cancer, 49
- PALA, in renal cell cancer, 49
- Pancreatic cancer
 - adjuvant therapy in, 582-599
 - chemoradiotherapy in, 584-585
 - failure pattern in, 582-584
 - incidence of, 582
 - neoadjuvant therapy of, 584
 - patient selection in, 585-586
 - postoperative chemotherapy in, 586-587
 - radioimmunodetection of, 450
 - surgery in, 586-587
- Partial hydatiform mole, 99, 115-116
 - reproduction following, 193-194

- Partial hydatiform mole (*Continued*)
 sonography of, 132
 villous contour of, 100
- Partial response, definition of, 42
- PBSC, see Peripheral blood stem cell(s)
- PCNU, in renal cell cancer, 48
- Peptic ulcer, in polycythemia rubra vera, 312
- Percutaneous ethanol injection therapy, for hepatic metastases, 504
- Periampullary duodenal carcinoma, hereditary factors in, 418-419
- Peripheral blood progenitor cell transplantation
 autologous BMT v, in breast cancer, 242-243
 in multiple myeloma, 232-234
 in ovarian cancer, 257-258
- Peripheral blood stem cell(s)
 circulating, evidence for, 202
 collection of, 204-205
 following high-dose HD therapy, 225-226
 harvesting of, see Stem cell harvesting
 identification of, 202-204
 infusion of, high-dose trials of, in breast cancer, 563
 mobilization complications of, 263-265
 mobilization of, 204
 reinfusion of
 in non-Hodgkin's lymphoma, 221-223
 in recurrent HD, 225
- Peripheral blood stem cell transplantation
 autologous, mortality following, 222
 autologous v allogeneic, 218-219
 blood centers and, 283-284
 in breast cancer, 238-249
 in chronic myelogenous leukemia, 401
 complications of, 263-270
 early, 205-206
 future directions in, 206-207, 271-290
 gene therapy in, 279-283
 graft engineering in, 277-278
 history of, 203
 immunomodulation in, 278-279
 intravenously transplanted, homing of, 278
 reinfusing lymphoma in, 223-224
 tumor decontamination in, 271-277
 tumor detection in, 272-273
 tumor purging in, 273
- Peripheral progenitor cell, cryopreserved, high-dose trials of, 563
- Persistent nonmetastatic gestational trophoblastic disease, 161-165
 chemotherapy for, 162-163
 diagnosis of, 161-162
 long-term prognosis of, 164
 outcomes in, 164
 surgery for, 163
- Personnel, for colon cancer screening, 441
- PET, see Positron emission tomography
- P-glycoprotein(s)
 expression of, 18-19
 in clinical trials, 24-26
 MDR 1 a, 18
- Philadelphia chromosome, in chronic granulocytic leukemia, 344-346, 380
- Phlebotomy
 aspirin plus, 316
 dipyridamole plus, 316
 in polycythemia rubra vera, 315
 thrombosis associated with, 315-316
- N-Phosphonacetyl-L-aspartic acid, in renal cell cancer, 49
- Phosphorus, radioactive, in polycythemia rubra vera, 315
- Pipbroman, in polycythemia rubra vera, 318
- Pirarubicin, in renal cell cancer, 48
- Piroxantrone, in renal cell cancer, 48
- Placenta, examination of, methods of, 117-118
- Placental site trophoblastic tumor, 116
 definition of, 104
 differential diagnosis of, 105
 pathology of, 104-105
 sonography of, 133
 therapy for, 163-164
- Platelet anti-aggregating therapy, in polycythemia rubra vera, 316
- Platelet distribution width, in polycythemia rubra vera, 312
- Platelet nucleotide ratio, in polycythemia rubra vera, 312
- Platelet-derived growth factor, in bone marrow fibrosis, 328
- Ploidy analysis, in gestational trophoblastic disease, 106
- PMS1, 419
 in colorectal cancer, 422
- PMS2, 419
 in colorectal cancer, 422
- Poly IC-LC, in renal cell cancer, 49
- Polyclonal antiplacental alkaline phosphatase, 106
- Polycythemia rubra vera, 307-326
 acute leukemia in, 314
 busulfan in, 317
 clinical features of, 310-312
 common signs in, 310
 course of, 313-314
 cytogenetics of, 346-348
 diagnosis of, 312-313
 diagnostic criteria for, 363
 differential diagnosis of, 364
 erythropoietin levels in, 308
 hydroxyurea in, 316-317
 incidence of, 307
 interferon-alfa in, 318
 laboratory abnormalities in, 311
 major features of, 368
 pathophysiology of, 307-310
 in patients under 40, 319
 phlebotomy in, 315
 pipbroman in, 318
 primary v secondary, 312-313
 proliferative stage of, 362
 special considerations in, 319-320
 spent phase of, 363
 surgery in, 319-320
 symptoms in, 310
 thrombo-hemorrhagic complications of, 311-312
 thrombocytosis in, 319
 treatment by age in, 319
 treatment of, 314-319

- Polymerase chain reaction, in stem cell tumor detection, 272-273
- Polyp(s)
colonic, familial clustering of, 441
detection of, in colon cancer, 437-439
- Portal vein adjuvant therapy
in colon cancer, 604-605
in colorectal cancer, 476-477
trials of, 477
- Positive predictive value, in colon cancer, 434
- Positron emission tomography
in colorectal cancer, 462-466
in gestational trophoblastic disease, 135-136
radio pharmaceuticals for, 463-464
- Postpolycythemia myeloid metaplasia, 313-314, 363
- Prednisone
in adjuvant hormonal therapy, of breast cancer, 555
melphalan plus, in multiple myeloma, 230
- Prednisone, cyclophosphamide, doxorubicin, vincristine, regimen, in CNS lymphomas, 537
- Pregnancy, essential thrombocythemia and, 338-339
- Pringle maneuver, 496
- Procarbazine, lomustine, vincristine regimen, in high-grade astrocytoma, 533
- Procarbazine, methotrexate, cyclophosphamide regimen, intra-arterial, in astrocytoma, 535
- Prodrug, 5-FU, 513-514
- Progesterone, as chemosensitizing agent, 23
- Prognostic factor(s)
in colorectal cancer, 472-473
DNA ploidy as, in colorectal cancer, 473
in hepatic resection, 498-500
- Prostate cancer
adjuvant systemic therapy of, 633-640
adjuvant therapy of, 634-638
early, conventional therapy of, 634-636
heterogeneity of, therapy implications of, 633-634
incidence of, 633
neoadjuvant therapy of, 634
stage classification of, 634
- Protein kinase-C, detection of, in colon cancer, 442-443
- Protein-bound polysaccharide, 594
- PU.1, 215
- Pulsatility index, definition of, 133
- Pump
implantable, for hepatic arterial infusion, 501-502
intrahepatic, 502-503
- Purines, in renal cell cancer, 53
- Pyrimidines, in renal cell cancer, 52-53
- Quinidine
as chemosensitizing agent, 23
vinblastine plus, 50
- Radiation therapy
of brain, 185-188
for gestational trophoblastic disease, 185-190
for hepatic metastases, 504-505
of liver, 188-190
- Radioimmunoassay, of human chorionic gonadotropin, 123-125
- Radioimmunodetection
of colorectal cancer, 448-451
of pancreatic cancer, 450
radionuclides for, 449
- Radioimmunoscintigraphy, in gestational trophoblastic disease, 135-136
- Radiolabeling, of monoclonal antibodies, clinical experience with, 36-37
- Radiopharmaceuticals
for PET imaging, 463-464
for radioimmunodetection, 449
- Radiotherapy
adjuvant
for melanoma, 657
in NSCLC, 572
in rectal cancer, 618
in agnogenic myeloid metaplasia, 331
chemotherapy alternating with, in head and neck cancer, 547
chemotherapy plus, see Chemoradiotherapy
combination chemotherapy plus
for head and neck cancer, 545-547
randomized trials of, 546
high-dose chemotherapy plus, in breast cancer, 563
in neoadjuvant trials, for head and neck cancer, 542-543
postoperative, in colon cancer, 606-607
preoperative, randomized trials of, 612-613
in primary brain tumor, 530
sandwich, in rectal cancer, 616
sphincter-sparing surgery plus, in rectal cancer, 618-621
- Radiotherapy, cisplatin, 5-FU regimen, in head and neck cancer, 547-548
- Ras gene, in colorectal cancer, 423-424
- Raynaud's phenomenon, in polycythemia rubra vera, 312
- RB1 gene, 349
- Reactive thrombocytosis
clinical features of, 336
clonal v, 336
conditions associated with, 335
C-reactive protein plasma levels in, 336
essential thrombocythemia v, 335
IL-6 plasma levels in, 336
- Receptor binding, in human chorionic gonadotropin, 123
- Rectal cancer
adjuvant radiotherapy in, 618
adjuvant therapy in, need for, 611
adjuvant trials in, 481-482
chemoradiotherapy issues in, 617-618
CT staging of, 454
endoscopic staging of, 454
folinic acid in, 617-618
5-FU in, 615
levamisole in, 617-618
local excision plus radiotherapy in, 619-620
lomustine in, 616
ongoing adjuvant trials in, 483
postoperative adjuvant therapy in, 613-616, 616
preoperative adjuvant therapy in, 611-613, 616
preoperative chemoradiotherapy trials in, 613
preoperative radiation plus surgery in, 620-621
preoperative radiotherapy trials in, 612-613
preoperative v postoperative adjuvant therapy in, 616-617

- Rectal cancer (*Continued*)
 radiotherapy in, 618-621
 sphincter-sparing surgery in, 618-621
 tumor markers in, as response prognosticators, 618
- Renal-cell carcinoma
 advanced, chemotherapy for, 42-60
 autolymphocyte cellular therapy in, 74-75
 cellular therapy in, 74-80
 familial, von Hippel-Lindau mutations in, 6
 gene therapeutic approaches to, 12-14
 gene therapy for, 81-91
 genetics of, 3-8
 high-dose IL-2 in, 61-66
 immunotherapeutic strategies in, 9-10
 incidence of, 3, 43
 introduction to, 1-2
 LAK cellular therapy in, 75-76
 low-dose IL-2 in, 67-73
 metastatic, surgery plus immunotherapy in, 31-32
 monoclonal antibodies reactive with, 34-35
 monoclonal antibody G250 in, 34-41
 mortality rates of, 43
 multiple drug resistance in, 19-22
 murine, studies in, 9-16
 nephron-sparing surgery in, 29-33
 radical nephrectomy in, 29
 sporadic, von Hippel-Lindau mutations in, 5-6
 tumor-infiltrating lymphocyte cellular therapy in, 76-78
 vena caval involvement in, 30-31
- Renca model, T lymphocyte-mediated immune responses against, 10
- Replication error, in colorectal cancer, 422-423
- Reproduction
 counseling for, 195-196
 following complete hydatidiform mole, 193
 following partial hydatidiform mole, 193-194
 following persistent gestational trophoblastic disease, 194-195
 following repeat molar pregnancy, 194
- Rescue, from chemotherapy toxicity, agents for, 517-519
- Reserpine, as chemosensitizing agent, 23
- Resistive index, definition of, 133
- Response, definition of, 42
- Retroperitoneal lymph node dissection, in stage II nonseminomatous testis cancer, 641-642
- Rhodamine-123, 211
- RNA, MDR 1, levels of, 20
- Rules of evidence, for screening, 488-489
- Screening
 age in, 440
 for colon cancer, 433-447
 intervals in, 440
 positive family history in, 440-441
 rules of evidence for, 488-489
- Semustine, 5-FU regimen
 in adjuvant chemotherapy, 474-475
 in adjuvant therapy, for melanoma, 647-649
 in chemoradiotherapy, for rectal cancer, 614
 in colorectal cancer, 475
- Severe combined immunodeficiency mice, engraftment in, 12
- Sialosyl-Tn antigen, in colorectal cancer, 426
- Sigmoidoscopy
 in colon cancer, 437-439
 rigid, 438
- Single strand conformational polymorphism gel, in von Hippel-Lindau disease, 4
- Sparfosic acid, in renal cell cancer, 49
- Sphincter-sparing surgery
 preoperative radiation plus, 620-621
 radiation plus, 618-621
- Spindle inhibitors, in renal cell cancer, 51-52
- Spirogermanium, in renal cell cancer, 49
- Spiromustine, 533
- Splenectomy, in agnogenic myeloid metaplasia, 330-331
- Stabilization of disease, definition of, 42
- Stage distribution, in colon cancer, 434
- Staging
 surgical, 472-473
 TNM, 472-473
- Stem cell harvesting
 complications of, 263-265
 gene therapy following, 279-283
 graft engineering following, 277-278
 immunomodulation following, 278-279
 positive selection in, 275-276
 purging plus positive selection in, 276-277
 tumor decontamination in, 271-277
 tumor purging in, 273-274
- Stem cell kinase-1 ligand, hematopoietic stem cell growth and, 213-214
- Steroids, in peripheral blood progenitor cell transplantation, 233
- STK-1, 213
- Streptozotocin, in renal cell cancer, 49
- Subclone, 343
- Suicide gene, 282-283
- Sulofenur, in renal cell cancer, 49
- Suramin, in renal cell cancer, 49
- Surgery
 in esophageal cancer, 586-587
 in gastric cancer, 586-587
 immunotherapy plus, 31-32
 in neoadjuvant trials, for head and neck cancer, 542-543
 nephron-sparing, 29-33
 in NSCLC, 572
 in pancreatic cancer, 586-587
 in polycythemia rubra vera, 319-320
 in primary brain tumor, 530
 in rectal cancer, 612
 sphincter-sparing, see Sphincter-sparing surgery
 trials of, in NSCLC, 573-576
- Surveillance, adjuvant therapy v, in testis cancer, 643
- T(5;2)(q31,p12) syndrome, 349-350
- T(8;9)(p11,34), 351
- T(8;9)(q22,34), 351
- T(9;2)(q34,q11.2)
 in chronic granulocytic leukemia, 344-346
 in myeloproliferative disorders, 341-343
- T-1 weighted image, definition of, 458
- T-2 weighted image, definition of, 458
- TAG-72 antigen, radioimmunodetection of, 448

- Tamoxifen
 in adjuvant chemotherapy, 553-554
 in chemohormonal therapy, 557
 as chemosensitizing agent, 23
 dose intensity of, 562-563
 in renal cell cancer, 49
- Tauromustine, in renal cell cancer, 49
- Taxol, *see* Paclitaxel
- Taxotere, in renal cell cancer, 49
- TE, in MRI, definition of, 458
- Technetium, radiolabeled, for imaging, 449
- Telomeres, 212
- Teniposide, in renal cell cancer, 49
- Testis cancer
 retroperitoneal metastases of, pathologic staging of, 642
 stage II
 prognostic factors in, 643
 relapse incidence in, 644
 stage II nonseminomatous
 adjuvant therapy in, 641-646
 staging in, 641-642
 surveillance v adjuvant therapy in, 643
- Theca-lutein cyst(s)
 complications of, 144
 CT of, 134
 incidence of, 139
 sonography of, 135
- 6-Thioguanine, in renal cell cancer, 49
- Thiotepa
 high-dose trials of, in breast cancer, 563
 in peripheral blood progenitor cell transplantation, 233
 postoperative, in gastric cancer, 590-592
- Thoracotomy, in esophageal cancer, 586
- Thrombocytopenia, primary, *see* Essential thrombocytopenia
- Thrombocytopenia, due to stem cell harvesting, 264
- Thrombocytosis
 anagrelide in, 319
 in polycythemia rubra vera, 319
 reactive, *see* Reactive thrombocytosis
- Thrombosis
 associated with phlebotomy, 315-316
 in polycythemia rubra vera, 311
- Thymidylate synthase
 as chemotherapeutic target, in colorectal cancer, 426-428
 fluorouracil inhibition of, 427
 inhibitors of, 514-515
- TNM staging, in colorectal cancer, 472-473
- Topoisomerase I inhibitor, 515-516
- Topotecan, 516
 in renal cell cancer, 49
- Toremifene, in renal cell cancer, 49
- Total body irradiation
 in matched sibling BMT, for chronic myelogenous leukemia, 406
 in multiple myeloma, 233
 in non-Hodgkin's lymphoma, 220-221
- Toxicity, of chemotherapy, protection from, 517-519
- TR, in MRI, definition of, 458
- Transcription factor, in hematopoietic cell development, 214-215
- Transfectant(s)
 antitumor effects of, 14
 production of, 13-14
- Transforming growth factor-beta, in bone marrow fibrosis, 327
- Transitional cell cancer, chemotherapy for, 625-626
- Trifluoperazine, as chemosensitizing agent, 23
- Triglycidylurazol, in renal cell cancer, 49
- Trimetrexate, in renal cell cancer, 49
- Trisomy 8, 351
- Trophoblastic tumor, nonvillous, 116-117
- Tumor-associated antigen
 in colorectal cancer, 425-426
 monoclonal antibodies reactive with, 34
- Tumor marker, in rectal cancer, as response prognosticator, 618
- Tumor purging
 chemical agents for, 274
 in stem cell collections, 273
- Tumor-infiltrating lymphocyte(s)
 IL-2 plus, 77-78
 in renal cell cancer, 76-78
 phase I-II trials of, 77
 UCLA trials of, 78
- Tumor-specific antigen, monoclonal antibodies reactive with, 34
- Tumor-targeting study, in renal-cell carcinoma, 35
- Tumorigenesis, von Hippel-Lindau mutations in, 3-8
- Turcot's syndrome, hereditary factors in, 418-419
- Ultrasonography
 endoluminal, 452-456
 in colorectal cancer, 451-457
 rectal, for tumor infiltration depth, 453
- Ultrasound
 Doppler, *see* Doppler ultrasound
 of gestational trophoblastic disease, 130-133
 intraoperative, *see* Intraoperative ultrasound
 of placental site trophoblastic tumor, 133
- Ultraviolet light, 275-276
- Uracil
 florafur plus, 513
 5-FU plus, in renal cell cancer, 47
- Uracil-tegafur, trials of, in NSCLC, 575-576
- Vaccine(s)
 Ab2, 37-40
 G250-related anti-idiotypic antibodies for, 37-38
 gene-transduced tumor, 84-85
 genetically altered tumor, 85-88
 for melanoma, 653-655
 strategies for, 88-90
- Vagina, gestational trophoblastic disease metastatic to, 139
- Vasquez-Osler disease, 307
- Vena cava, involvement of, in renal cell cancer, 30-31
- Verapamil, vinblastine plus, in renal cell cancer, 50
- Vinblastine
 cyclosporine-A plus, 50
 dipyrimadole plus, 50
 doxorubicin plus, 50
 floxadine plus, 46
 for invasive bladder cancer, 625
 in chemoradiotherapy, for NSCLC, 578

- Vinblastine (*Continued*)
 nifedipine plus, 50
 quinidine plus, 50
 verapamil plus, 50
Vinblastine, cisplatin, bleomycin regimen, 642-643
Vinblastine, cisplatin, methotrexate regimen, 625, 627
Vinblastine, methotrexate, doxorubicin regimen, 625, 627
Vincristine
 in adjuvant chemotherapy, 474-475
 in chemoradiotherapy, for rectal cancer, 614
 high-dose trials of, in breast cancer, 563
 in gestational trophoblastic disease, 147
 for melanoma, 654
 in peripheral blood progenitor cell transplantation, 233
Vincristine, cyclophosphamide, doxorubicin, dexamethasone regimen, in CNS lymphomas, 537
Vincristine, cyclophosphamide, doxorubicin, prednisone regimen, in CNS lymphomas, 537
Vincristine, doxorubicin, dexamethasone regimen
 in chronic myelogenous leukemia, 400-401
 in multiple myeloma, 230
Vincristine, methyl lomustine, 5-FU, regimen, in colorectal cancer, 427-428
Vincristine, procarbazine, lomustine, regimen, in high-grade astrocytoma, 533
Vindesine
 in neoadjuvant trials, for head and neck cancer, 542-543
 in renal cell cancer, 50
 trials of, in NSCLC, 575-576
Vinorelbine, in renal cell cancer, 48
Vitamin A, for melanoma, 656
Vitamin B12, in chronic granulocytic leukemia, 393
VLA-4, 213
VLA-5, 213
Volunteer bias, in colon cancer, 434
Von Hippel-Lindau disease
 clinical heterogeneity in, 4
 gene of, positional cloning for, 3-4
 incidence of, 3
 mutations of, 5-6
WHO prognostic index score
 for gestational trophoblastic disease, 146
 modified, 174
Whole brain radiation therapy
 dosing of, 187
 for metastatic gestational trophoblastic disease, 185-188
 side effects of, 188
 volume of, 187
Whole liver radiation therapy, 188
 for metastatic gestational trophoblastic disease, 188-190
 side effects of, 189-190
 volume of, 188-189
Wild-type p53 protein, 420
WR-2721, in tumor purging, 274
Yeast artificial chromosome contig, 4
ZD1694, 515

